Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases
Review
[키워드] ACE2
Admission
adverse outcomes
Angiotensin converting enzyme-2
anti-TNF
Bacterial infection
benefit
biologic
Biologic drugs
characteristic
chronic
Clinical characteristics
contrary
Corticosteroids
COVID-19
COVID-19 infection
Crohn’s disease
Cytokine storm
death
disease
disease course
drug
drugs
Effect
epidemiological data
excluded
facilitate
form
IBD
ICU
immune system
immunomodulators
immunosuppressive therapies
Immunosuppressive treatment
increased risk
Infection
Inflammatory bowel disease
infliximab
Influenza
intensive care
Patient
patients
Pneumonia
receptor
reduce mortality
replication of SARS-CoV-2
SARS-CoV-2
SARS-COV-2 infection
severity of COVID-19
shown
suppress
susceptibility
Tocilizumab
Topic
treated
ulcerative colitis
[DOI] 10.3390/children8090753 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/children8090753 PMC 바로가기 [Article Type] Review